Figure 6.

CX614-induced BDNF release activates/phosphorylates mTOR. a, Cultured cortical neurons (DIV14) were preincubated with TrkB-Fc (0.5 μg/ml, 1 h) before being treated with CX614 (10 μm, 1 h). At the end of treatment, cells were processed for immunoblotting with antibodies against actin and total and phosphorylated mTOR. Immunoblots were quantified and ratios of p-mTOR over total unphosphorylated mTOR were calculated; data were then expressed as fold of control and are means ± SEM from six independent experiments. *p < 0.001 compared with control; ^†p < 0.05 compared with CX614; ^#not significantly different from control (ANOVA followed by Tukey's posttest analysis). b–d, Acute hippocampal slices were treated with CX614 (50 μm) in the absence or presence of Ca²⁺ (b), the absence or presence of ryanodine (Ryan) (100 μm, c), or the absence or presence of nifedipine (Nife) (10 μm, d) for 1 h. At the end of treatment, tissues were processed for immunoblotting with antibodies against total and phosphorylated mTOR, and actin (as a loading control). Immunoblots were quantified and ratios of phosphorylated over total mTOR were calculated; data were then expressed as percentage of control and are means ± SEM from three or four independent experiments. *p < 0.01 compared with control; ^#not significantly different from control; ^†p < 0.01 compared with CX614-treated samples; ^‡p < 0.05 compared with CX614 (ANOVA followed by Tukey's posttest analysis).